Literature DB >> 8989244

Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases.

E B Mawer1, J Walls, A Howell, M Davies, W A Ratcliffe, N J Bundred.   

Abstract

1,25-dihydroxyvitamin D (1,25-(OH)2D) stimulates differentiation and controls proliferation in breast cancer cells. The role of endogenous 1,25-(OH)2D and its relation to PTH related protein (PTHrP) during the progression of breast cancer is not known; we therefore investigated these hormones in two studies. In a cross-sectional study of patients with breast cancer at different stages of disease, serum 1,25-(OH)2D levels (mean +/- SE) were highest in early disease (102 +/- 3.7 pmol/L), fell in normocalemic patients with bone metastases (52 +/- 5.3 pmol/L; P < 0.01), and were lowest in hypercalcemic patients (33 +/- 5.6 pmol/L; P < 0.001). PTHrP was detectable in the serum of only one normocalcemic patient with progressive metastases but was present in 11 of the 12 hypercalcemic patients, thus PTHrP did not stimulate 1,25-(OH)2D synthesis. In a 6-month longitudinal study of normocalcemic patients with bone metastases undergoing hormonal therapy, serum 1,25-(OH)2D concentrations fell in patients whose disease progressed (P = 0.0056), but remained constant in those who were stable or responded to treatment. These changes in 1,25-(OH)2D preceded clinical signs of progression and predicted disease response. In the progressive group, five of whom died during the study, 1,25-(OH)2D decreased between the initial and final samples, PTH fell significantly from 24.8 to 13.5 ng/L (P = 0.025), serum calcium rose from 2.27 to 2.39 mmol/L (P = 0.017), and the urinary calcium/creatinine ratio rose from 0.37 to 0.68 (P = 0.046). PTH and 1,25-(OH)2D were significantly correlated in the final samples from this group, Spearman's rank correlation = 0.80, P = 0.022. The results indicate that normocalcemia in these patients is maintained, at the expense of suppressing PTH and 1,25-(OH)2D, in the face of increased calcium released from lytic lesions in bone. Loss of the antiproliferative effects of 1,25-(OH)2D may then permit more rapid secondary growth of the tumor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989244     DOI: 10.1210/jcem.82.1.3642

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Serum 25-hydroxyvitamin D levels in early and advanced breast cancer.

Authors:  C Palmieri; T MacGregor; S Girgis; D Vigushin
Journal:  J Clin Pathol       Date:  2006-10-17       Impact factor: 3.411

2.  Low bone mineral density in adults with cystic fibrosis.

Authors:  C S Haworth; P L Selby; A K Webb; M E Dodd; H Musson; R McL Niven; G Economou; A W Horrocks; A J Freemont; E B Mawer; J E Adams
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

Review 3.  The role of vitamin D in cancer prevention.

Authors:  Cedric F Garland; Frank C Garland; Edward D Gorham; Martin Lipkin; Harold Newmark; Sharif B Mohr; Michael F Holick
Journal:  Am J Public Health       Date:  2005-12-27       Impact factor: 9.308

4.  Retinoids modulate expression of the endocytic partners megalin, cubilin, and disabled-2 and uptake of vitamin D-binding protein in human mammary cells.

Authors:  Timothy M Chlon; David A Taffany; Joellen Welsh; Matthew J Rowling
Journal:  J Nutr       Date:  2008-07       Impact factor: 4.798

5.  CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.

Authors:  Puneet Dhawan; Robert Wieder; Robert Weider; Sylvia Christakos
Journal:  J Biol Chem       Date:  2008-12-03       Impact factor: 5.157

6.  A prospective study of change in bone mineral density over one year in adults with cystic fibrosis.

Authors:  C S Haworth; P L Selby; A W Horrocks; E B Mawer; J E Adams; A K Webb
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

7.  Association of CKD and cancer risk in older people.

Authors:  Germaine Wong; Andrew Hayen; Jeremy R Chapman; Angela C Webster; Jie Jin Wang; Paul Mitchell; Jonathan C Craig
Journal:  J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 10.121

Review 8.  Breast cancer and the immune system.

Authors:  Leanna J Standish; Erin S Sweet; Jeffrey Novack; Cynthia A Wenner; Carly Bridge; Ana Nelson; Mark Martzen; Carolyn Torkelson
Journal:  J Soc Integr Oncol       Date:  2008

Review 9.  Vitamin D and the mammary gland: a review on its role in normal development and breast cancer.

Authors:  Nair Lopes; Joana Paredes; José Luis Costa; Bauke Ylstra; Fernando Schmitt
Journal:  Breast Cancer Res       Date:  2012-05-31       Impact factor: 6.466

10.  Transcriptional effects of 1,25 dihydroxyvitamin D(3) physiological and supra-physiological concentrations in breast cancer organotypic culture.

Authors:  Cintia Milani; Maria Lucia Hirata Katayama; Eduardo Carneiro de Lyra; JoEllen Welsh; Laura Tojeiro Campos; M Mitzi Brentani; Maria do Socorro Maciel; Rosimeire Aparecida Roela; Paulo Roberto del Valle; João Carlos Guedes Sampaio Góes; Suely Nonogaki; Rodrigo Esaki Tamura; Maria Aparecida Azevedo Koike Folgueira
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.